ALPMY News and Press, Astellas Pharma Inc. ADR From 07/16/19

TOKYO and BOTHELL, Wash. , July 16, 2019 /PRNewswire/ --  Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") and Seattle Genetics, Inc.  (Nasdaq:SGEN) today announced submission of a Biologics License Application for accelerated approval...

NORTHBROOK, Ill. , July 10, 2019 /PRNewswire/ -- Astellas today announced that Chelsea Glinski has been appointed national vice president, Oncology Sales, Astellas US. In this role, Glinski will oversee US sales for the XTANDI brand, and contribute to the growth and development of ...

France's Biophytis has filed an amended registration statement to offer 8.75M American Depositary Shares in its U.S. initial public offering . More news on: Cytokinetics, Incorporated, Astellas Pharma Inc., Eli Lilly and Company, Healthcare stocks news, IPO News Read more ...

Recently in the journal Nature , an article was published characterizing the oldest known example of a fungus. The organism, termed an Ourasphaira, was approximately one billion years old and was found in what was believed to be an ancient river bed in Canada. For comparison sake, the oldes...

The first patient has been dosed in a Phase 2 clinical trial, ARROW , evaluating Progenics Pharmaceuticals' (NASDAQ: PGNX ) I-131 1095 radiotherapy, combined with Pfizer (NYSE: PFE ) and Astellas' ( OTCPK:ALPMY )  XTANDI (enzalutamide), for the treatment of metastatic castration-res...

TOKYO and BOTHELL, Wash. , June 3, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) (President and CEO: Kenji Yasukawa , Ph.D., "Astellas") and Seattle Genetics, Inc.  (Nasdaq: SGEN) today announced that data from the first cohort of a pivotal phase 2 clinical&#x...

TOKYO , May 30, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D. "Astellas") today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to update the U.S. product labeling for XO...

Xencor ( XNCR ) was able to get the FDA to remove a clinical hold for its program using XmAb14045 to treat patients with relapsed/refractory acute myeloid leukemia. This is a big win for the company because many months ago, this program was put at a standstill after the FDA had put a partial...

Cytokinetics ( CYTK ) announced results from its phase 2 study using its drug reldesemtiv to treat patients with amyotrophic lateral sclerosis ((ALS)). The trial failed to meet the primary endpoint of the study; however, the drug was able to perform slightly better than placebo. It seeme...

Cytokinetics (NASDAQ: CYTK ) slumps  15%  premarket on light volume in reaction to unsuccessful results from a Phase 2 clinical trial, FORTITUDE-ALS , evaluating reldesemtiv (CK-2127107) in patients with amyotrophic lateral sclerosis (ALS). More news on: Cytokinetics, Incorpor...